Quarterly report · Q2

Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥112.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥55.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥97.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥51.2bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥36.3bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥17.6bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥61.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥37.3bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥38.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥62.2bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥24.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.8bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥25.0bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥26.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥12.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥42.7bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥25.8bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥377.7bnat 2022-09-30Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥308.4bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥86.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥291.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥237.7bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥284.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥231.4bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥100.2bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥87.0bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥25.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥18.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥14.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥13.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥35.442022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.582022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥60.092021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.862021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥35.422022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.572022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥60.042021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.832021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio75.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥701m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥231m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥8.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥445m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥179m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.5bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥634m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥14.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.7bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥347m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥185m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-07-01 → 2022-09-30¥22.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-09-30¥40.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥664m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥2m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥18.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥304m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥865m
—segment totalrevenue2022-04-01 → 2022-09-30¥113.9bn
—segment totalrevenue2022-07-01 → 2022-09-30¥55.9bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥111.2bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥54.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.7bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥1.0bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥36.9bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥17.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥1.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥2.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥1.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥520m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥376m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥8.2bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥7.8bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥364m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥338m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥979m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥10.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥5.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥9.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥5.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥483m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥288m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-09-30¥38.4bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2021-07-01 → 2021-09-30¥19.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-09-30¥37.1bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2021-07-01 → 2021-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥622m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-09-30¥16.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2021-07-01 → 2021-09-30¥8.5bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2021-07-01 → 2021-09-30¥11.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2021-07-01 → 2021-09-30¥11.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥12m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥1m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-09-30¥38.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2021-07-01 → 2021-09-30¥25.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥17.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥12.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥17.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥238m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥238m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥2.0bn
—segment totalrevenue2021-04-01 → 2021-09-30¥98.6bn
—segment totalrevenue2021-07-01 → 2021-09-30¥52.0bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥96.2bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥50.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥2.4bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥1.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥62.9bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥37.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 824
ItemContextValueUnit
Basic earnings loss per share IFRSPrior1YTDDuration60.09
Basic earnings loss per share IFRSCurrentYTDDuration35.44
Diluted earnings loss per share IFRSPrior1YTDDuration60.04
Diluted earnings loss per share IFRSCurrentYTDDuration35.42
Revenue IFRSPrior1QuarterDuration51244000000JPY
Revenue IFRSCurrentQuarterDuration55621000000JPY
Cost of sales IFRSPrior1QuarterDuration22193000000JPY
Cost of sales IFRSCurrentQuarterDuration23710000000JPY
Gross profit IFRSPrior1QuarterDuration29051000000JPY
Gross profit IFRSCurrentQuarterDuration31911000000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration13615000000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration15910000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration-270000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration425000000JPY
Gain on change in equity IFRSPrior1QuarterDuration21906000000JPY
Gain on change in equity IFRSCurrentQuarterDuration-JPY
Other income IFRSPrior1QuarterDuration147000000JPY
Other income IFRSCurrentQuarterDuration1139000000JPY
Other expenses IFRSPrior1QuarterDuration-71000000JPY
Other expenses IFRSCurrentQuarterDuration-34000000JPY
Operating profit loss IFRSPrior1QuarterDuration37290000000JPY
Operating profit loss IFRSCurrentQuarterDuration17599000000JPY
Finance income IFRSPrior1QuarterDuration185000000JPY
Finance income IFRSCurrentQuarterDuration736000000JPY
Finance costs IFRSPrior1QuarterDuration6000000JPY
Finance costs IFRSCurrentQuarterDuration16000000JPY
Profit loss before tax IFRSPrior1QuarterDuration37469000000JPY
Profit loss before tax IFRSCurrentQuarterDuration18319000000JPY
Income tax expense IFRSPrior1QuarterDuration11641000000JPY
Income tax expense IFRSCurrentQuarterDuration5841000000JPY
Profit loss IFRSPrior1QuarterDuration25828000000JPY
Profit loss IFRSCurrentQuarterDuration12478000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration25020000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration11933000000JPY
Profit loss attributable to non controlling interests IFRSPrior1QuarterDuration808000000JPY
Profit loss attributable to non controlling interests IFRSCurrentQuarterDuration546000000JPY
Profit loss IFRSPrior1QuarterDuration25828000000JPY
Profit loss IFRSCurrentQuarterDuration12478000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration36.86
Basic earnings loss per share IFRSCurrentQuarterDuration17.58
Diluted earnings loss per share IFRSPrior1QuarterDuration36.83
Diluted earnings loss per share IFRSCurrentQuarterDuration17.57
Profit loss IFRSPrior1YTDDuration42747000000JPY
Profit loss IFRSCurrentYTDDuration25966000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-10000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration28000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-10000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration28000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration182000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration7712000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass